Change in kidney function and the risk of death.

<p>Model 1 adjusted for age, race, gender, diabetes mellitus, hypertension, cardiovascular disease, hyperlipidemia, peripheral artery disease, cerebrovascular disease, chronic lung disease, hepatitis C, HIV, dementia and eGFR at time of cohort entry (T0). Reference group is patients with stable kidney function (eGFR slope).</p

Flow chart for cohort selection.

<p>Flow chart for cohort selection.</p

Renal function trajectory phenotypes.

<p>Renal function trajectory phenotypes.</p

Association between serum phosphorus and dementia subtypes.

<p>Association between serum phosphorus and dementia subtypes.</p

Demographic and clinical characteristics according to renal function trajectory.

<p>Demographic and clinical characteristics according to renal function trajectory.</p

Adjusted associations of improved eGFR slope, and declining eGFR slopes.

<p>Model adjusted for age, race, gender, diabetes mellitus, hypertension, cardiovascular disease, hyperlipidemia, peripheral artery disease, cerebrovascular disease, chronic lung disease, hepatitis C, HIV, dementia, and initial eGFR. Reference group is patients with stable eGFR slope.</p

Cohort design and timeline.

<p>Cohort design and timeline.</p

Renal function trajectories.

<p>Renal function trajectories.</p

Spline analyses for the relationship between serum phosphorus and risk of incident dementia with serum phosphorus probability distribution histogram represented in gray bars in the background.

<p>Fig 2a: Overall cohort. Fig 2b: Analysis was restricted to cohort participants with serum phosphorus level >2.5 mg/dl. Fig 2c: Analysis was restricted to cohort participants with serum phosphorus level >4.5 mg/dl.</p

Risk of death by trajectory.

<p>Model adjusted for age, race, gender, for age, race, gender, diabetes mellitus, hypertension, cardiovascular disease, hyperlipidemia, peripheral artery disease, cerebrovascular disease, chronic lung disease, hepatitis C, HIV, dementia, and eGFR at time of cohort entry (T0). Reference group is patients with stable kidney function before cohort entry (T0).</p